Techstars Doubles Down on European Commitment With the Launch of Two New Accelerator Programs in Paris and Stockholm
14.9.2021 11:00:00 EEST | Business Wire | Press release
Techstars, the worldwide network that helps entrepreneurs succeed, announces the launch of two new accelerator programs in Paris and Stockholm. The launch showcases Techstars’ commitment to investing in startup talent in Europe, where it plans to invest in more than 100 startups in 2022 through its various accelerator programs in seven countries. Both programs will be fully funded by Techstars, following the recent July close of a new $150 million fund, intended to support more local entrepreneurs looking for global exposure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005314/en/
A Techstars Accelerator Office (Photo: Business Wire)
The Paris Techstars Accelerator and Stockholm Techstars Accelerator will each accept 12 startups per class, who will benefit from up to $120k in funding alongside evergreen access to Techstars’ vast network of mentors, investors, alumni and corporate partners. The Paris accelerator will operate two classes per year, while Stockholm will run once in 2022 and twice per year from 2023 onwards. Applications for these accelerators open today and will close on 1 December 2021, with the first classes of both programs due to commence on 21 March 2022.
Applications will be accepted from startups across all high-growth sectors, both B2B and B2C, and successful applicants will have a strong founding team who are using technology to tackle complex problems, with a clear and scalable product-market fit.
The Paris and Stockholm Techstars Accelerator programs follow the recent appointment of French-born CEO, Maëlle Gavet, in January 2021. An experienced French entrepreneur and former executive at Compass and Booking.com, Gavet’s experience scaling companies across Europe will assist Techstars on its mission to help more entrepreneurs in more places transform the world through access to capital and a global network.
Techstars currently operates 47 accelerators in 33 cities and 12 countries around the world, and while it previously operated a Paris-based accelerator in partnership with corporate partners, the Stockholm Techstars Accelerator marks its first venture into Sweden as it eyes expansion opportunities across Europe. Since 2009 and 2010, the company has been actively supporting thousands of entrepreneurs in Paris and Stockholm, respectively, by hosting more than 90 Techstars Startup Weekend programs in both cities, in close collaboration with local ecosystem leaders. Additionally in Europe, Techstars operates programs in London, Amsterdam, Berlin, Oslo and Turin.
Since its inception in 2006, Techstars has invested in 2,589 companies, which today have a combined market capital valuation of $220.1 billion. It counts 15 unicorns among its accelerator graduates, including DigitalOcean, Chainalysis, PillPack and SendGrid. Techstars invests in approximately 500 startups and deploys approximately $130M per year, making it one of the largest investors in high-growth early-stage companies by volume in the world.
Maëlle Gavet, CEO of Techstars, said: “We believe in the power of local ecosystems and that life-changing ideas can come from anywhere in the world - you don’t need to be in Silicon Valley to be a success. At Techstars, we meet the founders where they are and use our local networks to give them access to world-class capital and investing opportunities they wouldn’t otherwise have. Paris and Stockholm are two of Europe’s most rapidly growing yet underserved tech hubs, and we know there is a huge amount of talent there ready to be harnessed.”
Applications to apply to the Paris Techstars Accelerator and Stockholm Techstars Accelerator are open now.
About Techstars
The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 2,589 companies with a combined market cap of more than $220.1B. www.techstars.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005314/en/
Contact information
Ballou PR
Fiona Houston: +44 7935 105 338
Kelly Horn: +44 7767 649 727
Techstars
Jennifer Pakradooni: +1 305 772 3834
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
